RNA-based therapeutics discovery and development company Silence Therapeutics has sold a further part of its holding of common shares in Arrowhead Pharmaceuticals, it announced on Monday. The AIM-traded firm had purchased 6,831,359 common shares of Arrowhead for a total consideration of $11.3m, as it announced on 13 January 2017, then representing 9.21% of Arrowhead. At the company's last balance sheet date on 30 June, the shareholding was marked-to-market and valued at £8.55m as an ...Den vollständigen Artikel lesen ...